Gan & Lee Pharmaceuticals. (SHA: 603087)

Gan & Lee Pharmaceuticals. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,500	2,443	2,890	3,306	2,825	483.22
Short-Term Investments	-	-	201.36	276.44	945.34	201.62
Trading Asset Securities	1,567	2,410	1,636	1,624	787.05	1,058
Cash & Short-Term Investments	5,067	4,853	4,728	5,206	4,557	1,743
Cash Growth	21.48%	2.66%	-9.20%	14.24%	161.45%	47.94%
Accounts Receivable	271.39	385.37	189.57	934.66	827.35	847.53
Other Receivables	4.07	-	0.99	0.16	0.96	4.68
Receivables	275.46	385.37	190.55	934.82	828.3	852.21
Inventory	1,028	860.51	648.65	651.33	493.48	471.35
Other Current Assets	117.89	76.73	97.36	77.95	80.55	43.43
Total Current Assets	6,488	6,176	5,664	6,870	5,960	3,110
Property, Plant & Equipment	3,876	3,886	3,661	2,595	2,149	1,890
Long-Term Investments	523.28	334.66	30	201.36	466.05	362.2
Other Intangible Assets	273.22	278.08	293.48	295.99	238.92	131.85
Long-Term Deferred Tax Assets	165.06	168.95	138.25	30.8	14.93	-
Long-Term Deferred Charges	839.42	821.97	743.19	588.87	544.27	474.85
Other Long-Term Assets	56.6	49.99	76.51	270.33	134.67	57.38
Total Assets	12,222	11,715	10,607	10,853	9,507	6,027
Accounts Payable	111.04	94.82	36.52	26.15	14.79	19.11
Accrued Expenses	167.51	192.54	190	173.04	183.07	110.03
Current Portion of Leases	-	2.18	5.69	5.07	-	-
Current Income Taxes Payable	18.81	1.42	1.35	106.32	53.35	137.44
Current Unearned Revenue	52.26	52.99	68.13	36.56	68.44	90.69
Other Current Liabilities	457.06	429.49	511.36	138.39	90.19	100.96
Total Current Liabilities	806.67	773.45	813.04	485.53	409.85	458.22
Long-Term Leases	3.67	5.45	8.33	12.17	-	-
Long-Term Unearned Revenue	171.13	179.63	187.63	141.98	125.77	71.07
Long-Term Deferred Tax Liabilities	21.86	-	-	36.15	31.78	25.91
Other Long-Term Liabilities	11.42	14	12.27	10.2	1.69	0.68
Total Liabilities	1,015	972.52	1,021	686.02	569.09	555.88
Common Stock	601.07	594.16	565.65	561.54	561.54	360.9
Additional Paid-In Capital	-	3,351	2,563	2,476	2,474	72.69
Retained Earnings	7,252	6,865	6,525	7,133	5,905	5,035
Treasury Stock	-200.85	-71.36	-71.36	-	-	-
Comprehensive Income & Other	3,554	3.82	3.44	-3.44	-1.55	2.18
Total Common Equity	11,207	10,743	9,586	10,167	8,939	5,471
Minority Interest	-	0	-0.16	-0.16	-0.16	-0.16
Shareholders' Equity	11,207	10,743	9,586	10,167	8,938	5,471
Total Liabilities & Equity	12,222	11,715	10,607	10,853	9,507	6,027
Total Debt	3.67	7.62	14.01	17.24	-	-
Net Cash (Debt)	5,063	4,846	4,714	5,189	4,557	1,743
Net Cash Growth	22.08%	2.80%	-9.16%	13.86%	161.45%	47.94%
Net Cash Per Share	8.59	8.55	8.37	9.25	8.55	3.45
Filing Date Shares Outstanding	618.18	590.05	561.54	561.54	561.54	505.26
Total Common Shares Outstanding	618.18	590.05	561.54	561.54	561.54	505.26
Working Capital	5,682	5,402	4,851	6,385	5,550	2,652
Book Value Per Share	18.13	18.21	17.07	18.11	15.92	10.83
Tangible Book Value	10,934	10,464	9,292	9,871	8,700	5,339
Tangible Book Value Per Share	17.69	17.73	16.55	17.58	15.49	10.57
Buildings	-	1,367	1,165	1,046	1,013	841.37
Machinery	-	1,474	1,237	1,263	1,171	1,014
Construction In Progress	-	2,007	2,003	874.91	410.12	383.12

Source: S&P Capital IQ. Standard template. Financial Sources.